Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to -$2.9 million.

  • BioRestorative Therapies' Free Cash Flow fell 6495.88% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.8 million, marking a year-over-year decrease of 4142.44%. This contributed to the annual value of -$8.3 million for FY2024, which is 2628.71% down from last year.
  • BioRestorative Therapies' Free Cash Flow amounted to -$2.9 million in Q3 2025, which was down 6495.88% from -$2.7 million recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Free Cash Flow peaked at -$629364.0 during Q3 2021, and registered a low of -$2.9 million during Q3 2025.
  • Its 5-year average for Free Cash Flow is -$1.7 million, with a median of -$1.7 million in 2022.
  • Per our database at Business Quant, BioRestorative Therapies' Free Cash Flow crashed by 12674.49% in 2022 and then skyrocketed by 1651.55% in 2023.
  • BioRestorative Therapies' Free Cash Flow (Quarter) stood at -$1.1 million in 2021, then plummeted by 44.83% to -$1.7 million in 2022, then grew by 0.02% to -$1.7 million in 2023, then tumbled by 42.36% to -$2.4 million in 2024, then decreased by 22.87% to -$2.9 million in 2025.
  • Its Free Cash Flow was -$2.9 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$2.8 million in Q1 2025.